Increased cardiovascular risk markers in obesity are associated with body adiposity: Role of leptin

Javier Gómez-Ambrosi; Javier Salvador; Camilo Silva; Carlos Pastor; Fernando Rotellar; María J. Gil; Javier A. Cienfuegos; Gema Frühbeck

doi:10.1160/TH06-02-0079

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 95(06): 991-996
DOI: 10.1160/TH06-02-0079

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Increased cardiovascular risk markers in obesity are associated with body adiposity: Role of leptin

Authors

Javier Gómez-Ambrosi

¹Metabolic Research Laboratory, Pamplona, Spain
Javier Salvador

²Department of Endocrinology, Pamplona, Spain
Camilo Silva

²Department of Endocrinology, Pamplona, Spain
Carlos Pastor

³Department of Surgery, Pamplona, Spain
Fernando Rotellar

³Department of Surgery, Pamplona, Spain
María J. Gil

⁴Department of Biochemistry; Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain
Javier A. Cienfuegos

³Department of Surgery, Pamplona, Spain
Gema Frühbeck

¹Metabolic Research Laboratory, Pamplona, Spain

²Department of Endocrinology, Pamplona, Spain

Abstract

Summary

Epidemiological studies have shown that obesity is associated with increased blood concentrations of proinflammatory factors and markers of endothelial dysfunction such as fibrinogen, C-reactive protein (CRP), and von Willebrand factor (vWF). We analyzed the association of these markers with percentage of body fat (BF), and the influence of leptin in a cross-sectional study of 1,089 subjects (366 men) aged 44 (34–53) [median (interquartile range)] years, who were classified as obese or non-obese according to BF estimated by whole-body air displacement plethysmography. Obesity was defined as BF ≥ 25% in men and ≥ 35% in women. Compared with non-obese subjects (mean ± SD), obese patients had higher concentrations of fibrinogen (312± 78 vs. 342 ± 81 mg/dl, P < 0.001), CRP (0.41 ± 0.75 vs. 0.75± 1. 04 mg/l, P = 0.014), vWF (107 ± 29 vs. 123 ± 55%, P < 0.001), and leptin (10.4 ± 6.5 vs. 37.5 ± 26. 1 ng/ml, P < 0.0001). A positive correlation was observed between BF and fibrinogen (r = 0.266; P < 0.0001), logCRP (r = 0.409; P < 0.0001), and vWF (r = 206; P < 0.0001). Leptin was correlated with fibrinogen (r = 0.219, P < 0.0001), logCRP (r = 0.339, P < 0.0001), and vWF (r = 0.124, P = 0.002), but the statistical significance was lost after including BF in adjusted-correlation and multivariate analysis, suggesting that they are not regulated by leptin per se. In conclusion, the obesity-associated increase in the circulating concentrations of fibrinogen, CRP, and vWF is highly associated to BF and apparently not determined by leptin.

Keywords

Obesity - adipose tissue - inflammation - leptin - insulin resistance

Volltext

Referenzen

References
1 Rosito GA, D’Agostino RB, Massaro J. et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91: 683-9.
2 Eckel RH, York DA, Rössner S. et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004; 110: 2968-75.
3 Visser M, Bouter LM, McQuillan GM. et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-5.
4 McLaughlin T, Abbasi F, Lamendola C. et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-12.
5 Frühbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem - Cardiovasc Hematol Agents 2004; 02: 197-208.
6 La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 04: 371-9.
7 Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2005; 19: 637-47.
8 Chu N, Spiegelman D, Hotamisligil GS. et al. Plasma insulin, leptin, and soluble TNF receptor levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001; 157: 495-503.
9 Jin X, Fukuda N, Su J. et al. Effects of leptin on endothelial function with OB-Rb gene transfer in Zucker fatty rats. Atherosclerosis 2003; 169: 225-33.
10 Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol 2004; 181: 1-10.
11 Collins AL, Saunders S, McCarthy HD. et al. With-in- and between-laboratory precision in the measurement of body volume using air displacement plethysmography and its effect on body composition assessment. Int J Obes Relat Metab Disord 2004; 28: 80-90.
12 Pi Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc 2000; 59: 505-9.
13 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
14 Prentice AM, Jebb SA. Beyond body mass index. Obes Rev 2001; 02: 141-7.
15 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
16 Blann AD, Bushell D, Davies A. et al. von Willebrand factor, the endothelium and obesity. Int J Obes Relat Metab Disord 1993; 17: 723-5.
17 Lemieux I, Pascot A, Prud’homme D. et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961-7.
18 Gómez-Ambrosi J, Salvador J, Páramo JA. et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002; 35: 315-20.
19 Bo M, Raspo S, Morra F. et al. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism 2004; 53: 984-8.
20 Frühbeck G. Screening and interventions for obesity in adults. Ann Intern Med 2004; 141: 245-6.
21 Söderberg S, Olsson T, Eliasson M. et al. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999; 245: 533-43.
22 Skurk T, van Harmelen V, Lee YM. et al. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 2002; 34: 659-63.
23 Chan JL, Bullen J, Stoyneva V. et al. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 2005; 90: 1618-24.
24 Gómez-Ambrosi J, Salvador J, Silva C. et al. Leptin therapy does not affect inflammatory markers. J Clin Endocrinol Metab 2005; 18: 3803.
25 van Dielen FM, van’t Veer C, Schols AM. et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001; 25: 1759-66.
26 Kazumi T, Kawaguchi A, Hirano T. et al. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 2003; 52: 1113-6.
27 Shamsuzzaman AS, Winnicki M, Wolk R. et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-5.
28 Hukshorn CJ, van Dielen FMH, Buurman WA. et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26: 504-9.
29 Hukshorn CJ, Lindeman JH, Toet KH. et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004; 89: 1773-8.
30 Canavan B, Salem RO, Schurgin S. et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab 2005; 90: 5779-85.
31 Popa C, Netea MG, Radstake TR. et al. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1195-8.
32 van Crevel R, Karyadi E, Netea MG. et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J Clin Endocrinol Metab 2002; 87: 758-63.
33 Ble A, Windham BG, Bandinelli S. et al. Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). Am J Cardiol 2005; 96: 991-5.
34 Guagnano MT, Romano M, Falco A. et al. Leptin increase is associated with markers of the hemostatic system in obese healthy women. J Thromb Haemost 2003; 01: 2330-4.
35 Engeli S, Feldpausch M, Gorzelniak K. et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-7.
36 Ouchi N, Kihara S, Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-4.
37 Shimomura I, Funahashi T, Takahashi M. et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 02: 800-3.
38 Calabro P, Chang DW, Willerson JT. et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-3.
39 Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-20.
40 Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-45.
41 Meigs JB, Mittleman MA, Nathan DM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-8.
42 Pradhan AD, Cook NR, Buring JE. et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003; 23: 650-5.
43 Conlan MG, Folsom AR, Finch A. et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-5.
44 Whincup PH, Danesh J, Walker M. et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23: 1764-70.
45 Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab 2004; 01: 10.
46 Erdogan D, Gullu H, Caliskan M. et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59: 1276-82.